CABINET: Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus

Commentary
Video

Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
David Zhen, MD, an expert on gastric cancer
Related Content
FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs

FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs

April 23rd 2024
Article

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer

Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer

April 16th 2024
Article

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Lower Radiation Levels Linked to Poorer Tumor Response in Esophageal Cancer

Lower Radiation Levels Linked to Poorer Tumor Response in Esophageal Cancer

April 10th 2024
Article

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Read More

Rivoceranib Improves PFS, but Misses on OS in Gastric/GEJ Cancer

Rivoceranib Improves PFS, but Misses on OS in Gastric/GEJ Cancer

April 9th 2024
Article

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.

Read More